A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor

Blood

Volumn 105, Issue 2, 2005, Pages 562-566

  Orita, Tetsuro ^a   Tsunoda, Hiroyuki ^a   Yabuta, Naohiro ^a   Nakano, Kiyotaka ^a   Yoshino, Takeshi ^a   Hirata, Yuichi ^a   Ohtomo, Toshihiko ^a   Nezu, Jun Ichi ^a   Sakumoto, Hirofumi ^a   Ono, Kouichiro ^a   Saito, Mikiyoshi ^a   Kumagai, Eiji ^a   Nanami, Masahiko ^a   Kaneko, Akihisa ^a   Yoshikubo, Takashi ^a   Tsuchiya, Masayuki ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TA136; MONOCLONAL ANTIBODY VB22B; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN BINDING; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHO CELL; CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC ENGINEERING; HALF LIFE TIME; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

EID: 19944429567     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-04-1482     Document Type: Article

References (26)

1. Schneider H, Chavovapong W, Matthews DJ, et al. Homodimerization of erythropoietin receptor by a bivalent monoclonal antibody triggers cell proliferation and differentiation of erythroid precursors. Blood. 1997;89:473-482.
2. Abe M, Yano S, Sakaba N, et al. Surrogate thrombopoietin. Immunology Lett. 1998;61:73-78.
3. Yonehara S, Ishii I, Yonehara M. A cell-killing monoclonal antibody (ANTI-Fas) to a cell surface antigen co-down regulated with the receptor of tumor necrosis factor. J Exp Med. 1989;169: 1747-1756.
4. Souri M, Vigon I, Penciolelli JF, et al. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell. 1990;63: 1137-1147.
5. Vigon L, Mornon JP, Cocault L, et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci U S A. 1992;89:5640-5644.
6. Skoda RC, Seldin DC, Chiang MK, et al. Murine c-mpl: a member of the hematopoietic growth factor receptor superfamily that transduces a proliferative signal. EMBO J. 1993;12:2645-2653.
7. Balimaier M, Germeshausen M, Schulze H, et al. c-mpl mutations are cause of congenital amegakaryocyticthrombocytopenia. Blood. 2001;97:139-146.
8. Germeshausen M, Balimaier M, Weite K. Implications of mutations in hematopoietic growth factor receptor genes in congenital cytopenias. Ann NY Acad Sci. 2001;938:305-320.
9. van den Oudenrijn S, Bruin M, Folman CC, et al. Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia. Br J Haematol. 2000;110:441-448.
10. de Sauvage FJ, Mass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by c-MPL ligand. Nature. 1994;369: 533-538.
11. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature, 1994;369:565-568.
12. Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell. 1994;77:1117-1124.
13. Kato T, Ogami K, Shimada Y, et al. Purification and characterization of thrombopoietin. J Biochem. 1995;118:229.
14. Kuter JD, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood. 2002;100:3457-3469.
15. Li J, Yang C, Xia Y, et al.Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98:3241-3248.
16. Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and differentiation factor. Blood. 2002;99:2599-2602.
17. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000;132:364-368.
18. Deng B, Banu N, Malloy B, et al. An agonist murine monoclonal antibody to the human c-mpl receptor stimulate megakaryocytopoiesis. Blood. 1998;92:1981-1988.
19. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 1991;108:193-199.
20. Ishiyama M, Miyazono Y, Sasamoto K, Ohkura Y, Ueno K. A highly water-soluble disulfonaied tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta. 1997;44: 1299-1305.
21. Steinberg AD. MRL-lpr/lpr disease: theories meet Fas. Semin Immunol. 1994;6:55-69.
22. Hudson PJ, Kortt AA. High avidity scFv multimers; diabodies and triabodies. J Immunol Methods. 1999;231:177-189.
23. Quentmeier H, Zaborski M, Graf G, Drexler HG. Expression of the receptor MPL and proliferative effects of its ligand thrombopoietin on human leukemia cells. Leukemia. 1996;10:297-310.
24. Debili N, Wendung F, Katz A, et al. The Mpl-Ligand or thrombopoietin or megakaryocyte growth and differentiation factor has both direct proliferative and differentiate activities on human megakaryocyte progenitors. Blood. 1995;86:2516-2525.
25. Andrews RG, Torok-Storb B, Bernstein ID. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood. 1983;62:124-132.
26. Drachmen JG, Kaushansky K. Dissecting the thrombopoietin receptor: function elements of the Mpl cytoplasmic domain. Proc Natl Acad Sci USA. 1997;94:2350-2355.